Developer docs
API playgroundTry for free, no card

Search company profiles

Microsure

Full company profile

uuid0000qok

Namestring
Microsure
Legal namestring
Microsure BV
Websiteurl
microsure.nl
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Microsure is a Netherlands-based medical robotics company developing robot-assisted systems for open microsurgery and supermicrosurgery. Founded in 2016 and headquartered at Science Park Eindhoven in Son en Breugel, within the Brainport Eindhoven medtech cluster, the company builds the MUSA platform — a surgeon console paired with a robotic arm cart that uses disposable instrument adapters to allow surgeons to operate with their own familiar microsurgical instruments (forceps, needle holders, scissors). The system applies software-based motion scaling (approximately 4× to 7×) and tremor filtration (attenuating 7–12 Hz physiological tremor at ~50 μm amplitude) to joystick inputs, enabling procedures on sub-millimeter anatomical structures such as lymphatic ducts, blood vessels, and nerves. The current flagship product is MUSA-3 (CE-marked May 2026, FDA clearance in progress), which builds on the clinical experience of its predecessor MUSA-2 (the world's first CE-certified microsurgical robot, launched 2019, now out of production).

The company has accumulated clinical evidence across approximately 50 patients at European academic medical centers including Maastricht UMC+ and Uppsala University Hospital, with studies spanning lymphatic surgery, free flap surgery, and peripheral nerve repair. Microsure has assembled a Medical Advisory Board of globally recognized microsurgeons (including Prof. Peter Neligan at University of Washington and Dr. Jesse Selber at Corewell Health) and integrated its platform with the Olympus OrbEye 3D 4K digital exoscope for heads-up microsurgery. The technology stack is sensor-based motion processing rather than learning-based AI; the differentiator is purpose-built engineering for open microsurgery rather than adaptation from laparoscopic systems.

Microsure generates revenue primarily through capital sales of the MUSA-3 system to hospitals and academic medical centers, supplemented by service and support, with a recently added leasing channel through kineo for capital-light hospital adoption. The go-to-market is enterprise field sales targeting leading European centers for clinical evidence generation and KOL adoption ahead of broader commercialization, supported by conference presence (EFSM, EURAPS, EPSRC, RAMSES, WSRM), peer-reviewed publications, and a Medical Advisory Board strategy. Ownership is venture-backed and private, with investors including Innovation Industries, EIC Fund, Invest-NL, kineo, BOM Ventures, TCIM, Venturing Tech, Eindhoven University of Technology, and the Dutch Ministry of Economic Affairs; the company has raised approximately €40M cumulatively and appointed Michel Therin (ex-Medtronic, ex-Siemens Healthineers) as Supervisory Board Chair in September 2025 ahead of its commercial phase.

Short descriptiontext

Microsure develops robot-assisted microsurgical systems (MUSA-3) that filter physiological tremor and scale hand movements, enabling surgeons to perform supermicrosurgery on sub-millimeter structures such as lymphatic ducts, blood vessels, and nerves at hospitals and academic medical centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSon En Breugel, Netherlands
HQ citystring
Son En Breugel
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
surgical robotics systems, robotic microsurgery, supermicrosurgery assistance, medical device manufacturer, precision surgical robots
Industry2 codes
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Surgical Robotics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1MUSA-3 Surgical Robot Sales
TypeHardware Sales
Description

Microsure generates revenue through the sale of its MUSA-3 microsurgical robot system to hospitals and medical centers. The company has entered into asset financing agreements with kineo to offer leasing options to hospitals adopting MUSA-3.

microsure.nl
2Service and Support
TypeProfessional Services
Description

Ongoing service, support, and potentially consumables associated with the MUSA-3 system and clinical partnerships.

microsure.nl
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MUSA-3
Description

Third-generation microsurgical robot with enhanced dexterity, tremor filtration, motion scaling, and ergonomic surgeon console for supermicrosurgery procedures.

microsure.nl
+1 more record
Core offering1 text field

Microsure develops and sells robot-assisted microsurgical systems, primarily the MUSA-3 platform, which enables surgeons to perform super-microsurgical procedures on sub-millimeter anatomical structures such as lymphatic ducts, blood vessels, and nerves. The system consists of a surgeon console with joysticks and a robotic arm cart, using disposable adapters that allow surgeons to operate with their own familiar microsurgical instruments. MUSA-3 applies motion scaling (~4x to 7x reduction) and software-based tremor filtration to deliver consistent precision for procedures such as lymphatic surgery, free flap surgery, and peripheral nerve repair.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Surgeons using MUSA achieved consistent anastomoses of 0.3mm vessels, a task extremely difficult by hand
+2 more records
Product overview1 text field

Microsure offers a portfolio of dedicated microsurgical robots centered on its MUSA platform. The current flagship product is MUSA-3, a third-generation robotic system for supermicrosurgery that consists of a surgeon console and robotic arm cart, using disposable adapters to enable surgeons to use their own trusted instruments. The earlier MUSA-2 (launched 2019) was the world's first CE-certified microsurgical robot and served as the clinical prototype for validating the technology; it is no longer in production. MUSA-3 builds on MUSA-2 with enhanced dexterity, wider workspace, improved tremor reduction, and regulatory approval (CE mark obtained May 2026).

Product and service1 record
1MUSA-3
CategorySurgical Robotics Hardware
Description

Third-generation microsurgical robot designed to assist surgeons during open super-microsurgical procedures by downscaling and stabilizing hand movements. Consists of a surgeon console with joysticks and a robotic arm cart using disposable adapters that allow surgeons to work with their own trusted microsurgical instruments. Features motion scaling (~4x and 7x), tremor filtration, ergonomic seated operation, and compatibility with digital or hybrid microscopes. CE marked (May 2026); intended for hospital microsurgery departments and reconstructive surgery centers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-04
Description

Key clinical partner conducting clinical studies with MUSA-2 and MUSA-3 systems for lymphatic surgery, free flap surgery, and peripheral nerve repair. Dr. Tom van Mulken from Maastricht UMC+ earned his PhD on advancements in robotic microsurgery.

2Uppsala Academic Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-04
Description

Clinical partner in Sweden conducting clinical studies and in-vitro research. Dr. Maria Mani from Uppsala University Hospital serves on Microsure's Medical Advisory Board.

microsure.nl
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

MMI develops the Symani surgical robot, the most direct competitor to MUSA-3 in microsurgical and supermicrosurgical robotics. Both target lymphatic, free flap, and peripheral nerve procedures with motion scaling and tremor filtration, competing for the same European academic reference centers.

TypeBroad incumbent
Description

Intuitive Surgical is the dominant surgical robotics incumbent with the da Vinci platform. It is not specialized in open microsurgery but sets the benchmark for hospital capital robotics purchasing decisions and represents the most significant long-term competitive threat as it expands indications.

TypeBroad incumbent
Description

Stryker is a broad medical device incumbent with the Mako robotics platform in orthopedics and a growing surgical technologies portfolio. As a large, well-capitalized player adjacent to surgical robotics, it could extend into microsurgical indications.

TypeBroad incumbent
Description

Medtronic's Hugo robotic-assisted surgery platform competes in general soft-tissue surgery and the company has deep hospital relationships across Europe. Its scale and balance sheet make it a credible potential entrant into adjacent microsurgical applications.

5Johnson & Johnson (Ethicon / Auris Health)
TypeBroad incumbent
Description

J&J's Ottava general surgery robotics platform (Ethicon) and the MONARCH bronchoscopy platform (Auris Health) make it a broad surgical robotics incumbent with the resources to compete in multiple specialty surgical categories over time.

TypeEmerging player
Description

CMR Surgical's Versius system is a portable, modular laparoscopic surgical robot that competes for hospital capital budgets in Europe. While not microsurgery-focused, it shares Microsure's enterprise sales motion and European hospital customer base.

TypeEmerging player
Description

Moon Surgical (with the Maestro system) is an emerging surgical robotics company backed by major medtech investors, focused on the laparoscopic operating room. It is comparable in stage, capital intensity, and enterprise sales model rather than in clinical indication.

TypeEmerging player
Description

Asensus Surgical (formerly TransEnterix) develops the Senhance surgical robotics platform with digital surgery features. It is an emerging surgical robotics competitor pursuing hospital accounts with a similar enterprise sales motion to Microsure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Microsure

Surgical Roboticsmicrosure.nl

Microsure develops robot-assisted microsurgical systems (MUSA-3) that filter physiological tremor and scale hand movements, enabling surgeons to perform supermicrosurgery on sub-millimeter structures such as lymphatic ducts, blood vessels, and nerves at hospitals and academic medical centers.

What Microsure does

Microsure is a Netherlands-based medical robotics company developing robot-assisted systems for open microsurgery and supermicrosurgery. Founded in 2016 and headquartered at Science Park Eindhoven in Son en Breugel, within the Brainport Eindhoven medtech cluster, the company builds the MUSA platform — a surgeon console paired with a robotic arm cart that uses disposable instrument adapters to allow surgeons to operate with their own familiar microsurgical instruments (forceps, needle holders, scissors). The system applies software-based motion scaling (approximately 4× to 7×) and tremor filtration (attenuating 7–12 Hz physiological tremor at ~50 μm amplitude) to joystick inputs, enabling procedures on sub-millimeter anatomical structures such as lymphatic ducts, blood vessels, and nerves. The current flagship product is MUSA-3 (CE-marked May 2026, FDA clearance in progress), which builds on the clinical experience of its predecessor MUSA-2 (the world's first CE-certified microsurgical robot, launched 2019, now out of production).

The company has accumulated clinical evidence across approximately 50 patients at European academic medical centers including Maastricht UMC+ and Uppsala University Hospital, with studies spanning lymphatic surgery, free flap surgery, and peripheral nerve repair. Microsure has assembled a Medical Advisory Board of globally recognized microsurgeons (including Prof. Peter Neligan at University of Washington and Dr. Jesse Selber at Corewell Health) and integrated its platform with the Olympus OrbEye 3D 4K digital exoscope for heads-up microsurgery. The technology stack is sensor-based motion processing rather than learning-based AI; the differentiator is purpose-built engineering for open microsurgery rather than adaptation from laparoscopic systems.

Microsure generates revenue primarily through capital sales of the MUSA-3 system to hospitals and academic medical centers, supplemented by service and support, with a recently added leasing channel through kineo for capital-light hospital adoption. The go-to-market is enterprise field sales targeting leading European centers for clinical evidence generation and KOL adoption ahead of broader commercialization, supported by conference presence (EFSM, EURAPS, EPSRC, RAMSES, WSRM), peer-reviewed publications, and a Medical Advisory Board strategy. Ownership is venture-backed and private, with investors including Innovation Industries, EIC Fund, Invest-NL, kineo, BOM Ventures, TCIM, Venturing Tech, Eindhoven University of Technology, and the Dutch Ministry of Economic Affairs; the company has raised approximately €40M cumulatively and appointed Michel Therin (ex-Medtronic, ex-Siemens Healthineers) as Supervisory Board Chair in September 2025 ahead of its commercial phase.

Microsure firmographics

Firmographics
Name
Microsure
Legal name
Microsure BV
Website
https://microsure.nl
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Microsure develops robot-assisted microsurgical systems (MUSA-3) that filter physiological tremor and scale hand movements, enabling surgeons to perform supermicrosurgery on sub-millimeter structures such as lymphatic ducts, blood vessels, and nerves at hospitals and academic medical centers.
Ownership category
akta.pro rank

Microsure industry classification

Industry
Product category
Surgical Robotics
NAICS
Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Surgical robotics systems
  • Robotic microsurgery
  • Supermicrosurgery assistance
  • Medical device manufacturer
  • Precision surgical robots

Where Microsure is headquartered

Location

Headquarters

HQ city
Son En Breugel
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Microsure business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. MUSA-3 Surgical Robot Sales: Microsure generates revenue through the sale of its MUSA-3 microsurgical robot system to hospitals and medical centers. The company has entered into asset financing agreements with kineo to offer leasing options to hospitals adopting MUSA-3.
  2. Service and Support: Ongoing service, support, and potentially consumables associated with the MUSA-3 system and clinical partnerships.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Microsure product offering

Product offering

Core offering

Microsure develops and sells robot-assisted microsurgical systems, primarily the MUSA-3 platform, which enables surgeons to perform super-microsurgical procedures on sub-millimeter anatomical structures such as lymphatic ducts, blood vessels, and nerves. The system consists of a surgeon console with joysticks and a robotic arm cart, using disposable adapters that allow surgeons to operate with their own familiar microsurgical instruments. MUSA-3 applies motion scaling (~4x to 7x reduction) and software-based tremor filtration to deliver consistent precision for procedures such as lymphatic surgery, free flap surgery, and peripheral nerve repair.

Product overview

Microsure offers a portfolio of dedicated microsurgical robots centered on its MUSA platform. The current flagship product is MUSA-3, a third-generation robotic system for supermicrosurgery that consists of a surgeon console and robotic arm cart, using disposable adapters to enable surgeons to use their own trusted instruments. The earlier MUSA-2 (launched 2019) was the world's first CE-certified microsurgical robot and served as the clinical prototype for validating the technology; it is no longer in production. MUSA-3 builds on MUSA-2 with enhanced dexterity, wider workspace, improved tremor reduction, and regulatory approval (CE mark obtained May 2026).

Differentiator

Problem solved

Functional benefit

Brands

  • MUSA-3: Third-generation microsurgical robot with enhanced dexterity, tremor filtration, motion scaling, and ergonomic surgeon console for supermicrosurgery procedures.
  • MUSA-2

Products and services

  • MUSA-3 Third-generation microsurgical robot designed to assist surgeons during open super-microsurgical procedures by downscaling and stabilizing hand movements. Consists of a surgeon console with joysticks and a robotic arm cart using disposable adapters that allow surgeons to work with their own trusted microsurgical instruments. Features motion scaling (~4x and 7x), tremor filtration, ergonomic seated operation, and compatibility with digital or hybrid microscopes. CE marked (May 2026); intended for hospital microsurgery departments and reconstructive surgery centers.

Quantifiable outcome

  • Surgeons using MUSA achieved consistent anastomoses of 0.3mm vessels, a task extremely difficult by hand
  • +2 more outcomes

Companies that use Microsure

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles2 records

Microsure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature5 records

Microsure partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Maastricht UMC+coreStrategic or Co-development Partner · 4 October 2023Key clinical partner conducting clinical studies with MUSA-2 and MUSA-3 systems for lymphatic surgery, free flap surgery, and peripheral nerve repair. Dr. Tom van Mulken from Maastricht UMC+ earned his PhD on advancements in robotic microsurgery.
  • Uppsala Academic HospitalcoreStrategic or Co-development Partner · 4 October 2023Clinical partner in Sweden conducting clinical studies and in-vitro research. Dr. Maria Mani from Uppsala University Hospital serves on Microsure's Medical Advisory Board.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Microsure competitors and assessment

Company assessment

Direct peers

  • Medical Microinstruments (MMI): MMI develops the Symani surgical robot, the most direct competitor to MUSA-3 in microsurgical and supermicrosurgical robotics. Both target lymphatic, free flap, and peripheral nerve procedures with motion scaling and tremor filtration, competing for the same European academic reference centers.

Broad incumbents

  • Intuitive Surgical: Intuitive Surgical is the dominant surgical robotics incumbent with the da Vinci platform. It is not specialized in open microsurgery but sets the benchmark for hospital capital robotics purchasing decisions and represents the most significant long-term competitive threat as it expands indications.
  • Stryker: Stryker is a broad medical device incumbent with the Mako robotics platform in orthopedics and a growing surgical technologies portfolio. As a large, well-capitalized player adjacent to surgical robotics, it could extend into microsurgical indications.
  • Medtronic: Medtronic's Hugo robotic-assisted surgery platform competes in general soft-tissue surgery and the company has deep hospital relationships across Europe. Its scale and balance sheet make it a credible potential entrant into adjacent microsurgical applications.
  • Johnson & Johnson (Ethicon / Auris Health): J&J's Ottava general surgery robotics platform (Ethicon) and the MONARCH bronchoscopy platform (Auris Health) make it a broad surgical robotics incumbent with the resources to compete in multiple specialty surgical categories over time.

Emerging players

  • CMR Surgical: CMR Surgical's Versius system is a portable, modular laparoscopic surgical robot that competes for hospital capital budgets in Europe. While not microsurgery-focused, it shares Microsure's enterprise sales motion and European hospital customer base.
  • Moon Surgical: Moon Surgical (with the Maestro system) is an emerging surgical robotics company backed by major medtech investors, focused on the laparoscopic operating room. It is comparable in stage, capital intensity, and enterprise sales model rather than in clinical indication.
  • Asensus Surgical: Asensus Surgical (formerly TransEnterix) develops the Senhance surgical robotics platform with digital surgery features. It is an emerging surgical robotics competitor pursuing hospital accounts with a similar enterprise sales motion to Microsure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Microsure social profiles

Digital presence

Microsure compliance and trust

Trust signal

Compliance3 records

Microsure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Microsure leadership team

Management profile

Number of profiles

Profiles5 records

Microsure funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Microsure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Microsure

What does Microsure do?

Microsure develops and sells robot-assisted microsurgical systems, primarily the MUSA-3 platform, which enables surgeons to perform super-microsurgical procedures on sub-millimeter anatomical structures such as lymphatic ducts, blood vessels, and nerves. The system consists of a surgeon console with joysticks and a robotic arm cart, using disposable adapters that allow surgeons to operate with their own familiar microsurgical instruments. MUSA-3 applies motion scaling (~4x to 7x reduction) and software-based tremor filtration to deliver consistent precision for procedures such as lymphatic surgery, free flap surgery, and peripheral nerve repair.

Is Microsure a public or private company?

Microsure is a private company. It is classified as venture growth investor backed and is currently operating.

When was Microsure founded?

Microsure was founded in 2016. It employs 51 to 100 people.

Where is Microsure based?

Microsure is headquartered in Son En Breugel, Netherlands, in the Europe region.

How does Microsure make money?

Two revenue lines are on record. MUSA-3 Surgical Robot Sales are the primary driver. The others are service and Support.

Who are Microsure's main competitors?

Medical Microinstruments (MMI) is listed as a direct peer. Broad incumbents are Intuitive Surgical, Stryker, Medtronic and Johnson & Johnson (Ethicon / Auris Health). Emerging players are CMR Surgical, Moon Surgical and Asensus Surgical.

Does Microsure have an API?

No public API is recorded for Microsure.

What industry is Microsure in?

Microsure's product category is Surgical Robotics. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkMicrosure receives CE mark for MUSA-3 system and appoints new CEOMicrosure received CE mark approval for its MUSA-3 system and appointed Alex Joseph as CEO, replacing Iwan van Vijfeijken. The approval enables clinical deployment across Europe, with the company now focusing on generating clinical evidence and supporting adoption among medical centres.PR NewswireMicrosure Announces CE Mark Approval and CEO Transition as Company Enters Next Phase of Clinical GrowthMicrosure announced CE mark approval for its MUSA-3 surgical robotics system and appointed Alex Joseph as CEO, succeeding Iwan van Vijfeijken. The CE mark enables clinical use in Europe, marking the company's transition from product development to a commercial medical device business. The company will focus on generating clinical evidence and building adoption at leading European medical centers.Eindhoven University of TechnologyPrecision robot transforms reconstructive microsurgeryMicrosurgeon Tom van Mulken defended his PhD thesis at Maastricht University on October 18th, validating the safety and capabilities of the MUSA3 surgical robot developed by Microsure in collaboration with Eindhoven University of Technology. The robotic system enables submillimeter precision for reconstructive microsurgery, aiming to reduce complications, improve patient recovery times, and lower long-term healthcare costs. The technology is currently undergoing further testing and pilot setups for widespread hospital implementation.G-MedtechMicrosure Closes €38M Series B2 Financing to Advance MUSA-3 Microsurgical RobotMicrosure has secured €38 million in Series B2 financing to advance the development of its MUSA-3 microsurgical robot, aiming for clinical studies toward US FDA clearance and CE mark. The funding will facilitate the completion of this advanced technology, which enhances surgical precision and ergonomics for various procedures. The financing round included participation from several new investors, highlighting interest in innovative medical technologies.Medical BuyerMicrosure secures €38M to advance its microsurgical robot, MUSA-3Microsure secured €38 million in Series B2 funding to finalize the development of its MUSA-3 microsurgical robot for clinical studies and subsequent regulatory approvals. The investment round includes new backers such as the European Innovation Council Fund and kineo, with plans to pursue FDA clearance in the USA and CE-mark certification in Europe.MicrosureMicrosure secures €38 million to advance its microsurgical robot, MUSA-3Microsure has secured €38 million in Series B2 funding to finalize the development of its MUSA-3 microsurgical robot. The company plans to conduct clinical studies and pursue FDA clearance in the United States and CE-mark certification in Europe with this capital. New investors including the European Innovation Council Fund and kineo have joined existing shareholders to support this expansion.MedicaldesigndevelopmentMicrosure Secures €38M to Advance its Microsurgical RobotMicrosure has closed its Series B2 investment round, securing €38 million to finalize the development of its MUSA-3 microsurgical robot for clinical studies and regulatory approval. The funding is provided by new investors including kineo and the European Innovation Council Fund, alongside existing shareholders such as Innovation Industries and Invest-NL. This capital will support the company's path toward FDA clearance in the USA and CE-mark certification in Europe.FinSMEsMicrosure Raises €38M in Series B2 FundingMicrosure, a robot-assisted microsurgery company based in the Netherlands, raised €38M in Series B2 funding from investors including the European Innovation Council Fund and kineo. The company plans to use the capital to finalize clinical studies for its new MUSA-3 surgical robot and pursue regulatory clearance in the USA and Europe.Silicon CanalsDutch-based Microsure raises €38M to boost robot-assisted microsurgery: Know moreMicrosure, a Netherlands-based company focused on robot-assisted microsurgery, has raised €38M in its Series B2 funding round to advance its latest microsurgical robot, MUSA-3, towards clinical trials and regulatory approval. The funding round included investments from notable entities such as Invest-NL and the European Innovation Council Fund, showcasing strong support for innovative healthcare technologies. Microsure's developments are expected to significantly improve microsurgery precision and patient outcomes, while also aiming to reduce healthcare costs.